CureSearch for Children’s Cancer has officially announced that Dr. Robbie Majzner of the Dana-Farber Cancer Institute is the recipient of the 2026 CureSearch Catapult Award, a prestigious $2 million grant aimed at accelerating the transition of high-potential cancer research from the laboratory to the bedside. This significant investment, co-funded by the Jeff Gordon Children’s Foundation, is earmarked for a Phase I clinical trial of a next-generation Chimeric Antigen Receptor (CAR) T-cell therapy specifically engineered for children and young adults battling relapsed or refractory neuroblastoma. This move represents a critical milestone in pediatric oncology, targeting a disease that remains one of the most lethal solid tumors in children.
The Catapult Award is a strategic funding mechanism designed to address the "valley of death" in drug development—the precarious gap between initial laboratory discovery and the commencement of human clinical trials. In the landscape of pediatric medicine, this gap is often wider due to the smaller patient populations and limited commercial incentives for pharmaceutical companies compared to adult cancers. By providing $2 million at this pivotal juncture, CureSearch and the Jeff Gordon Children’s Foundation are ensuring that a promising biological breakthrough does not stall due to a lack of resources, but instead moves forward to provide a potential lifeline for families who have exhausted standard treatment options.
The Challenge of High-Risk Neuroblastoma
Neuroblastoma is a cancer that develops from immature nerve cells found in several areas of the body, most commonly arising in and around the adrenal glands. It is the most frequent extracranial solid tumor in infants and children, accounting for approximately 7% to 10% of all pediatric oncology cases. Despite its relatively low incidence compared to adult cancers, it is responsible for a disproportionate number of childhood cancer deaths—more than 10% of the total.
For patients diagnosed with high-risk neuroblastoma, the clinical outlook is challenging. Current standard-of-care protocols involve a grueling regimen of high-dose chemotherapy, surgical resection, radiation therapy, and stem cell transplants, followed by immunotherapy. While these intensive interventions have improved outcomes over the last two decades, the five-year survival rate for high-risk cases still hovers below 50%. Furthermore, for those who do achieve remission, the risk of relapse remains high, and the long-term side effects of such aggressive treatments can lead to lifelong health complications, including hearing loss, cardiac issues, and secondary malignancies. When the disease returns—referred to as relapsed or refractory neuroblastoma—it often becomes resistant to conventional therapies, leaving clinicians with few remaining tools to combat the progression.
Evolutionary Leap in CAR T-Cell Technology
The therapy being advanced by Dr. Majzner and his team at Dana-Farber represents a sophisticated evolution of immunotherapy. CAR T-cell therapy involves harvesting a patient’s own T-cells—the "soldiers" of the immune system—and genetically re-engineering them in a laboratory to express specific receptors on their surface. These receptors allow the T-cells to recognize and bind to specific proteins, or antigens, found on the surface of cancer cells. Once infused back into the patient, these "living drugs" seek out and destroy the malignancy.
While CAR T-cell therapy has achieved revolutionary success in treating liquid cancers, such as certain types of leukemia and lymphoma, its application in solid tumors like neuroblastoma has been hampered by several biological hurdles. One of the primary obstacles is "T-cell exhaustion." In the harsh microenvironment of a solid tumor, the engineered T-cells often become overstimulated and lose their efficacy, eventually stopping their attack before the tumor is eradicated.
Dr. Majzner’s research focuses on overcoming this exhaustion. The new therapy targets GD2, a sugar-fat molecule (ganglioside) that is highly expressed on the surface of neuroblastoma cells but has limited expression in healthy tissues, making it an ideal target. However, unlike previous GD2-targeted therapies, Dr. Majzner’s team has incorporated a novel signaling protein called ZAP70 into the CAR architecture. This modification is designed to optimize the internal signaling of the T-cell, allowing it to remain active and persistent for longer periods within the patient’s body.
In preclinical models, this redesigned CAR T-cell showed significantly enhanced anti-tumor activity and improved persistence compared to traditional models. Furthermore, the data suggests a potentially improved safety profile, reducing the risk of off-target effects that have complicated earlier generations of GD2 therapies.
Chronology of Development and Clinical Trial Roadmap
The journey to the 2026 Catapult Award began in the research laboratories of Dana-Farber, where Dr. Majzner’s team spent years refining the ZAP70 signaling mechanism. Following successful proof-of-concept studies in vitro, the team moved into complex animal models, which confirmed that the "next-generation" cells could effectively shrink neuroblastoma tumors that were resistant to standard CAR T-cell approaches.

With the $2 million infusion from CureSearch and the Jeff Gordon Children’s Foundation, the project now enters the clinical phase. The upcoming Phase I trial will be conducted at Dana-Farber Cancer Institute and potentially other collaborating pediatric hospitals. The primary objectives of a Phase I trial are to:
- Assess Safety: Determine the maximum tolerated dose and identify any adverse side effects.
- Evaluate Persistence: Measure how long the engineered T-cells stay active in the patient’s bloodstream.
- Observe Initial Efficacy: Monitor the tumor response in children and young adults with relapsed or refractory neuroblastoma.
This trial is expected to provide the foundational data necessary to move into larger Phase II trials, which would focus more heavily on the therapy’s effectiveness across a broader patient population.
Strategic Collaboration and Official Responses
The selection of Dr. Majzner for the Catapult Award underscores a rigorous vetting process involving CureSearch’s Scientific Advisory Council, which consists of leading experts in pediatric oncology. The partnership with the Jeff Gordon Children’s Foundation further highlights the collaborative nature of modern medical philanthropy.
Dr. Robbie Majzner emphasized the necessity of this funding in moving the needle for patient care. "Current GD2 CAR T cells only work in patients with small amounts of disease," Dr. Majzner stated. "We’ve designed a brand-new CAR architecture that breaks past limitations to success in lab models, and this trial will allow us to bring this advanced therapy to the children who need it most. The CureSearch Catapult Award is vital to our mission; it gives us the momentum to catapult this science out of the lab and directly to the forefront of patient care."
Echoing this sentiment, Dr. Paisley Myers, Senior Director of Research & Programs at CureSearch, highlighted the organization’s commitment to translational research. "One of the greatest challenges in pediatric cancer research is ensuring that promising discoveries reach children," Dr. Myers noted. "Through the Catapult Award, CureSearch helps move innovative therapies from the laboratory into clinical trials. Dr. Majzner’s work exemplifies the bold, high-potential research we were created to support."
Analysis of Broader Implications for Pediatric Oncology
The implications of Dr. Majzner’s work extend far beyond neuroblastoma. If the ZAP70 signaling protein successfully prevents T-cell exhaustion in human subjects, this "architecture" could serve as a blueprint for treating other pediatric and adult solid tumors. Cancers such as osteosarcoma, Ewing sarcoma, and certain brain tumors also express GD2 or similar antigens, and they face the same challenges regarding the immunosuppressive tumor microenvironment.
Furthermore, this award highlights a shift in how pediatric cancer research is funded. As federal funding often prioritizes broad-spectrum research or adult-centric studies, private foundations like CureSearch and the Jeff Gordon Children’s Foundation are increasingly taking on the role of "venture philanthropists." They identify high-risk, high-reward projects that have the potential to disrupt the status quo and provide the targeted capital needed to move them into the clinic.
From a clinical perspective, the success of this trial would represent a move toward "precision immunotherapy." By refining the internal mechanics of the T-cell rather than just its external target, researchers are beginning to treat the immune system as a programmable platform. This level of customization is seen as the future of oncology, where treatments are tailored not just to the type of cancer, but to the specific biological failures that allow the cancer to evade the immune system.
Conclusion and Future Outlook
As the 2026 Phase I trial commences, the pediatric oncology community will be watching closely. For the families of children with high-risk neuroblastoma, the news provides a renewed sense of hope. While the road to a widely available cure remains long and fraught with regulatory and biological challenges, the Catapult Award ensures that the most promising science is given the opportunity to succeed.
The investment in Dr. Majzner’s work is a testament to the belief that through rigorous science and strategic funding, the survival statistics for childhood cancer can be rewritten. As the trial progresses, the data gathered will not only inform the treatment of neuroblastoma but will also contribute to the global understanding of how to harness the human immune system to conquer the most resilient forms of cancer. Through the continued support of the community and the dedication of researchers at institutions like Dana-Farber, the gap between discovery and care continues to shrink, bringing the goal of a cancer-free future for children closer to reality.

